The present research work is focused on the development of solid lipid nanoparticles of cefuroxime axetil (CA-SLN) for its enhanced inhibitory activity against Staphylococcus aureus produced biofilm. CA-SLN was prepared by solvent emulsification/evaporation method using single lipid (stearic acid (SA)) and binary lipids (SA and tristearin (TS)). Process variables such as volume of dispersion medium, concentration of surfactant, homogenization speed and time were optimized. The prepared SLN were characterized for encapsulation efficiency, drug polymer interaction studies (DSC and FT-IR), shape and surface morphology (SEM and AFM), in vitro drug release, stability studies and in vitro anti biofilm activity against S. aureus biofilm. Among the process variables, increased volume of dispersion medium, homogenization speed and time led to increase in particle size whereas increase in surfactant concentration decreased the particle size. SLN prepared using binary lipids exhibited higher entrapment efficiency than the single lipid. DSC and FT-IR studies showed no incompatible interaction between drug and excipients. CA-SLN showed two folds higher anti-biofilm activity in vitro than pristine CA against S. aureus biofilm.

目前的研究工作集中在头孢呋辛酯（CA-SLN）的固体脂质纳米颗粒的开发，因为它对金黄色葡萄球菌产生的生物膜具有增强的抑制活性。CA-SLN通过溶剂乳化/蒸发法使用单一脂质（硬脂酸（SA））和二元脂质（SA和三硬脂精（TS））制备。优化了工艺变量，例如分散介质的体积，表面活性剂的浓度，均化速度和时间。制备的SLN的特征在于包封效率，药物聚合物相互作用研究（DSC和FT-IR），形状和表面形态（SEM和AFM），体外药物释放，稳定性研究以及针对金黄色葡萄球菌的体外抗生物膜活性。生物膜。在工艺变量中，分散介质的体积增加，均质化速度和时间导致粒径增加，而表面活性剂浓度的增加则粒径减小。使用二元脂质制备的SLN表现出比单一脂质更高的包封效率。DSC和FT-IR研究表明，药物与赋形剂之间没有不相容的相互作用。与原始CA相比，CA-SLN对金黄色葡萄球菌生物膜的体外抗生物膜活性高出两倍。